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Background: Sleep is an essential component of good physical and mental health. Previous studies have reported
that poor quality sleep is associated with an increased risk of hypertension and cardiovascular disease. Hypertension
is the most common and important risk factor for cardiovascular disease, and even modest reductions in blood
pressure can result in significant reductions in the risk of stroke and myocardial infarction. In this trial, we will
determine the efficacy of an online sleep intervention in improving blood pressure, in participants with
hypertension and poor sleep quality.
Methods: Trial design: Randomized-controlled, two-group, parallel, blinded, single-center, Phase II trial of 134 participants.
Population and recruitment: Primary prevention population of participants with hypertension (systolic blood pressure,
130 to 160 mm Hg; diastolic blood pressure, <110 mm Hg) and poor sleep quality in a community setting. Intervention:
Multicomponent online sleep intervention consisting of sleep information, sleep hygiene education, and cognitive
behavioral therapy. Comparator: Standardized cardiovascular risk factor and lifestyle-education session (usual care).
Primary outcome: Change in mean 24-hour ambulatory systolic blood pressure between baseline and 8-week follow-up.
Hypertension has been selected as the primary outcome measure because of its robust association with both poor sleep
quality and cardiovascular disease. Statistical analyses: Intention-to-treat analysis by using a linear mixed model.
Trial registration: ClinicalTrials.gov: NCT01809821, registered March 8, 2013.
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Insufficient or poor quality sleep and cardiovascular risk
Sleep is an essential component of good physical and
mental health. However, the average sleep duration in the
Western world has steadily declined over the past decade
[1]. In the National Health Interview Survey 2004 to 2007,
more than one third of the North American adult popula-
tion was noted to have an abnormal duration of sleep, de-
fined as too short (<7 to 8 hours per night) or too long
(>8 hours per night) [2]. Previous laboratory and epidemi-
ologic studies showed that inadequate sleep patterns, in
terms of both quality and quantity, are associated with an
increased frequency of cardiovascular risk factors such as
hypertension, diabetes mellitus, and obesity [3,4], as well
as independently associated with an increased risk of* Correspondence: emcgrath2@partners.org
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unless otherwise stated.adverse cardiovascular outcomes, such as stroke and myo-
cardial infarction [5,6]. A meta-analysis of 16 prospective
cohort studies reported a significant association between
sleep of short duration (≤5 to 6 hours per night) and long
duration (>8 to 9 hours per night) and an increased risk of
all cause-mortality [7]. Therefore, insufficient or poor-
quality sleep is a common risk factor for cardiovascular
disease (CVD) and all-cause mortality, and represents a
potentially important population-based modifiable target
for CVD prevention.
Inadequate sleep and hypertension
A number of epidemiologic studies have reported an asso-
ciation between inadequate sleep, in terms of duration and
quality, and an increased risk of hypertension [1,8-10]. A
cross-sectional study among healthy adolescents reported
an association between actigraphy-defined low sleep effi-
ciency (an objective measure of sleep quality, defined as
the percentage of time in bed estimated to be asleep) andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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factors (OR, 3.5; 95% CI, 1.5 to 8.0) [11].
Furthermore, in a substudy of 578 adults from the
Coronary Artery Risk Development in Young Adults
study, actigraphy-measured shorter sleep duration and
lower sleep maintenance (a component of sleep quality de-
fined as the percentage of time between initial sleep onset
and final waking that is spent sleeping), were noted in a
cross-sectional analysis to be associated with significantly
higher systolic and diastolic blood pressures, after adjust-
ing for confounders such as age and antihypertensive
medications. In a longitudinal analysis of this cohort,
shorter average sleep duration also predicted significantly
increased odds of incident hypertension over 5 years (OR,
1.37; 95% CI, 1.05 to 1.78) [12]. In addition, a longitudinal
analysis of data from the National Health and Nutrition
Examination Survey of >4,500 US adults, reported a sig-
nificantly increased risk of hypertension in individuals
sleeping ≤5 hours per night compared with those sleeping
for 7 to 8 hours per night, after adjusting for various po-
tential confounders (HR, 1.32; 95% CI, 1.02 to 1.71) [1].
Mechanism underlying the association between poor
sleep and hypertension
The mechanism underlying the association between insuf-
ficient or poor-quality sleep and hypertension is proposed
to be multifactorial, including increased sympathetic ner-
vous system activity and increased prevalence of inter-
mediate risk factors, such as poor diet, reduced physical
activity, increased weight, and smoking [13]. Laboratory
studies have noted significantly increased sympathetic
activity and blood pressure in individuals in a sleep-
restricted condition, compared with individuals in a sleep-
recovery condition [14-17]. Increased urinary excretion of
noradrenaline, indicating increased sympathetic activity,
has also been reported after a night of sleep deprivation
[15,17]. Increased activity of the sympathetic nervous
system can lead to vasoconstriction as well as fluid reten-
tion, which can lead to hypertension through volume
overload [18].
Blood pressure and heart rate typically exhibit diurnal
variation. During sleep, a nocturnal dip occurs in both
blood pressure and heart rate, which remain low until
the time of awakening. Reduced sleep duration can re-
sult in longer exposure to enhanced sympathetic activity
and increased average 24-hour blood pressure and heart
rate. In this way, habitual sleep restriction can lead to
prolonged enhanced sympathetic nervous system activ-
ity, the development of hypertension, and subsequently,
an increased risk of stroke and other CVD [1].
Poor sleep and other cardiovascular risk factors
The mechanism underlying the association between
poor sleep and other key risk factors for CVD, such asdiabetes mellitus and obesity, is thought to be due to
sleep-related disruption in metabolic, endocrine, and im-
mune functions. Insufficient sleep has been associated
with elevated evening cortisol concentrations, which can
result in reduced sensitivity to insulin; increased levels
of growth hormone, which can cause a transient insulin
resistance; and increased sympathetic nervous system
activity, which can inhibit insulin secretion from the
pancreas [13,14,19]. Thus, sleep-induced disruption of
the endocrine and autonomic systems could explain the
observed association between inadequate sleep and in-
creased occurrence of diabetes mellitus.
Curtailed sleep has also been associated with reduced
levels of leptin, a hormone released by adipocytes, which
promotes satiety, and increased levels of ghrelin, a hor-
mone secreted by the stomach and pancreas that stimu-
lates appetite, as well as an increase in subjective feelings
of hunger. Thus, this provides a possible mechanism for
the observed association between inadequate sleep and
obesity [20,21]. Increased activity of the sympathetic
nervous system, with resultant hypertension, is thought
to be the underlying pathophysiologic mechanism link-
ing insufficient sleep with diabetes, obesity, and CVD
[18]. In turn, these factors also contribute to an increase
in blood pressure.
Current educational interventions to modify traditional
cardiovascular risk factors
Currently, stroke and other CVDs are the leading causes
of mortality in Europe and North America. Existing in-
terventions to tackle the huge burden of CVD in the
population include education on lifestyle modification,
as well as the use of primary and secondary preventive
therapies [22]. Educational interventions typically consist
of advice and information on modifiable risk factors,
such as smoking, alcohol consumption, physical activity,
and dietary practices. Although factors such as poor diet
and lack of physical activity clearly play a central role,
another possible contributor to the current epidemic of
CVD, mediated through hypertension and the metabolic
syndrome, is insufficient or poor-quality sleep [13].
Modifiability of poor sleep and the potential role of a
sleep intervention in CVD prevention
Insufficient or poor sleep quality is a modifiable risk factor
for CVD and could potentially be improved through the
use of a simple, low-cost, multicomponent intervention
aimed at improving sleep quality and quantity. Three
previous randomized controlled trials investigating the
efficacy of an intervention to improve sleep in participants
with insomnia reported significant improvements in sleep
efficiency, sleep latency and wakefulness after sleep onset
(measures of sleep quality), as well as improvements in
mental health and energy [23-25]. Improving sleep quality
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tion and prevention of cardiovascular risk factors, such as
hypertension [1,12,26]. Despite its apparent importance, no
previous randomized controlled trials have investigated the
efficacy of a sleep intervention for lowering blood pressure
or reducing the risk of CVD.
In this randomized controlled trial, we evaluate the ef-
ficacy of a sleep intervention in controlling blood pres-
sure and other vascular risk factors in a primary
prevention population of individuals with hypertension
and poor sleep quality.
Primary aim
To determine whether the addition of a multicompo-
nent, online, sleep intervention to usual care (standard
cardiovascular risk factor education), results in a greater
reduction in mean 24-hour systolic blood pressure (SBP)
in participants with hypertension and poor sleep quality,
compared with usual care alone, over an 8-week period.
Secondary aims
1. To determine whether the addition of a
multicomponent, online, sleep intervention to usual
care results in a greater reduction in mean 24-hour
diastolic blood pressure (DBP) in participants with
hypertension and poor sleep quality, compared with
usual care alone, over an 8-week period.
2. To determine whether the addition of a
multicomponent, online, sleep intervention to usual
care results in greater improvements in body mass
index (BMI), plasma lipids, plasma HbA1c,
estimated glomerular filtration rate (eGFR), mean
number of cigarettes smoked per day, Sleep
Condition Indicator (SCI) Score, Insomnia Severity
Index (ISI) score, Pittsburgh Sleep Quality Index
(PSQI) score, sleep-onset latency (SOL), wake time
to sleep onset (WASO), sleep efficiency, total sleep
time (TST), Beck Depression Inventory (BDI) score
and Beck Anxiety Inventory (BAI) score, in participants
with hypertension and poor sleep quality, compared
with usual care alone, over an 8-week period.
3. To determine whether level of adherence to the sleep
intervention influences the change in mean 24-hour
SBP over an 8–week period.
4. To determine whether concomitant use of
antihypertensive medication influences the change in
mean 24-hour SBP over an 8–week period.
Methods
Trial design
Randomized, two-group, parallel, blinded, controlled,
single-center trial. This is a Phase II, efficacy, proof-of-
principle trial with an allocation ratio of 1:1.Setting: Identification of participants and description of
center
Participants are recruited via advertisements in local
newspapers, advertisements on local radio stations, local
and online (Twitter and Facebook) poster advertise-
ments, and local public screening events. Interested
participants with hypertension (average SBP readings be-
tween 130 and 160 mm Hg with average DBP <110 mm
Hg) are referred to the Health Research Board Clinical
Research Facility Galway (HRB-CRFG) to be screened
for trial eligibility. Those who meet the eligibility criteria
are then referred to Croí House, Galway City, for base-
line risk factor assessment and for provision of written
informed consent. Croí House is an established cardio-
vascular risk factor modification center that provides
medical assessment, risk-factor profiling, and educa-
tional sessions on cardiovascular risk-factor modification
to the local population. Eligible participants are random-
ized into two management groups: (a) usual care +
online sleep intervention, and (b) usual care.
Choice of study population
Our study is a Phase II trial. A primary prevention popula-
tion of participants with no previous CVD and poor sleep
quality has been chosen because of the high likelihood of
such participants being responsive to the intervention and
demonstrating a reduction in blood pressure with the
intervention. Potential participants already receiving an-
tihypertensive medications are eligible for inclusion in
the trial. However, participants with diabetes mellitus
and chronic renal impairment are excluded, which
should reduce the proportion of participants that will
have changes to their blood-pressure medications over
the course of the trial.
Eligibility criteria
Inclusion criteria
1. Signed written informed consent
2. ≥ 18 years on entry to study
3. Average automated SBP monitor readings between
130 and 160 mm Hg with average automated DBP
monitor readings <110 mm Hg on three occasions,
measured in a valid standardized manner while
seated; or average 24-hour ambulatory blood
pressure monitoring (ABPM) SBP readings
between 130 to 160 mm Hg with average DBP
readings <110 mm Hg.
4. Self-reported difficulty getting to sleep (defined as
usually taking more than 30 minutes to get to sleep),
and/or staying asleep (usually waking up more than
once per night) for at least 3 months’ duration
5. Internet access, self-reported competency in using
the Internet, and regular Internet use
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1. Currently receiving more than two antihypertensive
medications, or recent (within previous 8 weeks)
change in type or dose of antihypertensive
medications or planned change in antihypertensive
medication in next 8 weeks.
2. History of myocardial infarction, ischemic stroke, or
transient ischemic attack
3. History of congestive heart failure
4. History of dialysis or evidence of chronic kidney
disease (eGFR <60)
5. History of diabetes mellitus
6. Current ongoing sleep-hygiene education or sleep-related
cognitive behavioral therapy
7. Ongoing involvement in night-shift work
8. History of obstructive sleep apnea (OSA) and
previously received or currently receiving treatment
for OSA (participants with a history of untreated
OSA are eligible for inclusion).
9. Known history of sleep disorders (that is, narcolepsy;
hypersomnias; parasomnias such as sleep walking,
night terrors, recurring nightmares; periodic limb
movements/restless-leg syndrome; circadian rhythm
sleep disorder)
10.Unable to follow educational advice in the opinion
of the clinician
11.Baby or young children at home that wake during
the night
12.History of bipolar affective disorder
13.History of psychosis
14.History of major depression (defined as depression
requiring hospitalization in the past or visit to
psychiatry outpatient clinic in the past 3 months)
15.Unstable depression (unstable is defined as
changes in antidepressant medications within
the last 3 months (that is, starting a new
medication, stopping a medication, or changing
a medication dose).
16.Unstable anxiety disorders/panic attacks (unstable
is defined as changes in anxiolytic medications
within the last 3 months (that is, starting a new
medication, stopping a medication, or changing a
medication dose).
17.Ongoing substance or alcohol abuse
18.Planned surgery or hospitalization during the trial
19.Incapacitating pain or illness or other medical
condition in which, in the opinion of the
clinician, the sleep intervention is unlikely to
be effective.
Participants who are currently taking medications associ-
ated with sleep disturbances are not excluded from this
study, provided they have been stable on those medicationsfor >3 months (stable is no start, stop, or change in dose in
past 3 months). These medications include:
 antidepressants (selective serotonin reuptake




 decongestants (pseudoephedrine, phenylephrine,
phenyl propanolamine)
 narcotic analgesics (oxycodone, codeine,
propoxyphene)
 cardiac medications such as β-blockers, α-receptor
agonists and antagonists, diuretics, and lipid-
lowering agents
 pulmonary medications (theophylline and albuterol)
Randomization
A randomization strategy using randomly permuted blocks
of varying block size is being used, which allows the assign-
ment schedule to be preplanned before participant recruit-
ment. The randomization schedule is constructed by using
a computer-generated list of pseudo-random numbers. A
centrally administered, computer-generated randomization
scheme is being used to assign individual participants ran-
domly in a 1:1 ratio, to either the intervention or control
groups. Once a participant is deemed eligible for trial entry
and has provided written informed consent, a researcher
assigns a unique study-identification number to the partici-
pant and contacts the online sleep intervention (Sleepio)
team with the participant's name, their assigned participant
number, and contact details (Email address and telephone
number). The Sleepio team then assigns the participant
to the next available randomization number on the list,
corresponding to a particular treatment assignment (Slee-
pio intervention or control). Participants randomized to
Sleepio receive a code via Email to access the online
sleep intervention. The Sleepio team holds the central
record of all participants who have been randomized,
along with the corresponding randomization numbers
and treatment-group assignments. All investigators at
the HRB-CRFG, including the statistician, are blinded
to participant treatment-group assignment. At the
end of the trial, treatment assignments will be com-
pared with the randomization list, to detect any incor-
rect assignments, and following completion of statistical
analyses, all investigators and trial personnel will be
unblinded.
Blinding
Trial participants, investigators, data collectors, statisti-
cian, and outcome assessors are blinded to study-group
assignment. Members of the Sleepio team assigning par-
ticipants to treatment groups are not blinded. Participant
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ioral lifestyle intervention is being compared with a con-
trol, and describe the intervention as general education on
cardiovascular risk factors. It is also mentioned that as-
pects of the intervention are delivered via online web ses-
sions, as well as through face-to-face sessions. Cardiology
research nurses deliver the usual care intervention (that is,
the cardiovascular education intervention) to participants
in both treatment arms.
All laboratory measurements are carried out in a
blinded fashion. Laboratory samples, with the exception
of HbA1c serum levels, are frozen and then stored, and
will be analyzed at the end of the trial. Serum HbA1c
levels are measured on the day of collection. Blood pres-
sure measurements are recorded in a blinded fashion by
using a 24-hour automated blood pressure monitor, thus
avoiding observer bias. All other study measurements,
including BMI and questionnaire scores, are interpreted
and entered into the study database in a blinded fashion
by a trained researcher. Because of the nature of the
intervention, a requirement for breaking the blinding to
access the randomization schedule for a particular par-
ticipant during the trial is not anticipated.
Study interventions
Components of the sleep intervention
The sleep intervention (Sleepio) is a multicomponent
online intervention consisting of sleep information and
sleep-hygiene education, along with behavioral and
cognitive components. This intervention was developed
after consultation with a sleep psychologist. It is based
on three previous randomized controlled trials investi-
gating the efficacy of an intervention to improve sleep in
participants with insomnia, one of which was an online
cognitive behavioral therapy intervention for chronic
insomnia disorder [25]. The interventions were similar,
with two of the trials showing a significant improvement
in sleep efficiency [23,25], and the third showing a
significant improvement in sleep latency, wakefulness
after sleep onset, and sleep efficiency (measures of sleep
quality), as well as improvements in mental health and
energy [24].
Participants in the sleep-intervention arm also receive
”usual” care (standardized cardiovascular risk-factor edu-
cation program), similar to participants in the control
arm. Thus, the comparison is: standardized cardiovascu-
lar education + online sleep intervention versus stan-
dardized cardiovascular education.
Multicomponent online sleep intervention
Sleep information and sleep-hygiene education
The participant is educated on the need for sleep and
its functions, the effects of sleep loss, factors adversely
affecting sleep, and the impact of lifestyle habits andenvironmental factors on sleep. Participants are educated
on a series of practical steps to improve sleep hygiene:
 Avoid caffeinated beverages, nicotine, or other
stimulants 6 hours before bedtime.
 Avoid alcohol, excessive fluids, and large meals,
3 hours before planned bedtime. Eliminate
”nightcaps”.
 Avoid excessive alcohol intake (14 units for females,
21 units for males, recommend no more than 2
drinks per day)
 Avoid illicit drugs
 Engage in regular physical activity, early in the day.
 Avoid stress and excitement, such as vigorous
exercise, in the 2 hours before bedtime
 Avoid intense mental activity requiring a high level
of concentration, including computer work, in the
2 hours before planned bedtime.
 Avoid mental activities such as planning or thinking
while in bed.
 Maintain an appropriate sleeping environment, in
terms of light, noise, ambient temperature, and
comfortable mattress/blankets.
 Stimulus control: limit the use of the bedroom to
sleeping, with avoidance of nonsleep behaviors such
as watching television or reading in the sleep
environment. Remove incompatible activities from
the bedroom environment (for example, television,
books). The aim is to break associations between the
sleeping environment and being awake, to re-
associate the bedroom with sleep, and to stay in the
bedroom only when asleep or feeling sleepy.
Sleep scheduling and sleep restriction
To help participants to reshape sleep patterns to corres-
pond with their individual sleep needs. The participant
is helped to reestablish a consistent sleep-wake schedule.
 Define individual sleep requirements.
 Develop a good pre-sleep routine
 Establish a strong bed-sleep connection
 Eliminate wakefulness from bed (rising if not asleep
within around 20 to 30 minutes)
 Establish and follow a regular and consistent
night-to-night sleep schedule, go to sleep in the
same bed at the same time each night, and arise
immediately on awakening at the same time each
morning
 Increase sleep efficiency through scheduling sleep in
relation to current total sleep; restrict participants’
allowed time in bed to the actual sleeping time
according to the participants’ sleep diary. Adjust the
time-in-bed period as sleep efficiency improves from
week to week. Participants are instructed to get up
Table 1 Summary of online sleep intervention
Treatment content Sleep information/education, sleep
hygiene, relaxation, stimulus control,
sleep restriction, cognitive techniques
(restructuring, paradox, mindfulness,
imagery, putting day to rest, thought
stopping)
Duration Six sessions over a minimum of 6 weeks
Delivery context Fully online




Appointment system, interactive sessions,
dynamic feedback against personal goals,
progress review at start of each session,
automatic calculation of sleep data over





progress, online Wikipedia of
sleep-educational topics. Social
community of users, moderated by
experts. Support/prompts/reminders
by Email and mobile SMS ”Graduation
ceremony” on course completion
McGrath et al. Trials 2014, 15:393 Page 6 of 11
http://www.trialsjournal.com/content/15/1/393at a regular time, even if they did not have enough
sleep the night before
 Avoid daytime naps
 Avoid recovery sleep as compensation
 Encourage and support people in changing their
sleep routines to improve 7-day per week
compliance
Cognitive therapy
The participant learns about ways to reduce mental
alertness, repetitive thoughts and anxiety that interfere
with sleep:
 Identify thought patterns and content that interfere
with sleep
 Develop accurate beliefs and attitudes about sleep
and sleep loss
 Prepare mentally for bed by putting the day to rest
 Learn thought-distraction and imagery techniques
 Teach progressive relaxation techniques; the
participant is taught how to recognize and control
muscular tension through use of exercise
instructions
 Use these techniques to combat intrusive thoughts
 Reduce efforts to control sleep and allow it to
happen naturally
 Encourage and support people in changing their
mental approach and to maintain behavior and
cognitive change
 Further adjust sleep schedules to maintain sleep
efficiency
Administration of the sleep intervention
Participants receive six weekly sessions delivered by an
animated “virtual therapist” (The Prof ). These sessions
are self-delivered at a convenient time for each partici-
pant, over an 8-week period. The program comprises
a fully automated media-rich web application, driven
dynamically by baseline, adherence, performance, and
progress data. At the start of each session, the Prof con-
ducts a progress review with the participant, explores
the diary data submitted during the week, the partici-
pant’s current sleep status and pattern, and progress
achieved against goals previously set. Underlying algo-
rithms feed the delivery of information and provide sup-
port and advice in a personally tailored manner. The
content of the cognitive behavioral therapy component
of the intervention is consistent with the literature, and
covers behavioral (for example, sleep restriction, stimu-
lus control) and cognitive (for example, putting the day
to rest, thought restructuring, imagery, articulatory sup-
pression, paradoxical intention, mindfulness) strategies,
as well as additional relaxation strategies (progressive
muscle relaxation and autogenic training) and advice onlifestyle and bedroom factors (sleep hygiene). The inter-
vention is based on a previously validated manual
[24,27]. Table 1 summarizes the content and features of
the intervention.Methods to maximize participant adherence to the
intervention and follow-up procedures
To improve adherence with follow-up procedures, we
schedule follow-up visits at a convenient time for partic-
ipants and ensure that adequate study staff and an effi-
cient system are in place, to minimize waiting times.
Participants access an online daily sleep diary through-
out the online sleep intervention, which is completed
each morning on rising. Participants are able to set auto-
mated mobile text message and/or Email prompts as re-
minders, to further promote adherence. Members of the
Sleepio team also contact participants who are not ad-
hering to the intervention by using standardized Emails
and phone follow-up, further to encourage adherence to
the intervention.
To reduce losses to follow-up, participants who fail to
return for a follow-up visit are contacted by phone and/
or mail to arrange an alternative convenient appoint-
ment.. The cost of transport to and from the study site
is reimbursed on request, further to encourage adher-
ence to the follow-up procedures. If participants are un-
able to make a final follow-up visit to the study site, a
home visit with the participant is arranged, where pos-
sible, to obtain final outcome data. If the participant re-
fuses or is unable to attend for any further follow-up
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dance. We believe these measures will help ensure a
high adherence rate of >85% and a low loss-to-follow-up
rate of <5%, thus maximizing the ability of the trial to
detect a true treatment effect.
Components of the control intervention
The control intervention consists of advice and education
on modifying cardiovascular risk factors and adopting a
healthier lifestyle. Specific components include advice on
smoking cessation, decreasing alcohol intake, increasing
physical activity levels, and adopting a healthy diet. This
standardized cardiovascular-risk-factor educational ses-
sion, which represents usual care, is administered in an
identical fashion, to trial participants in both arms.
Administration of the control intervention
Specialist nurses with specific training in cardiovascular-
risk-factor education (working for Croí), administer
the cardiovascular-risk-factor education intervention to
participants in groups of one to 15 (current average, six
to 10), over a 30–minute period. The control interven-
tion is delivered during week 1 of the trial.
Follow-up schedule
During the initial visit, all eligible participants who pro-
vide written informed consent are randomized. Mea-
surements are carried out on two occasions, at baseline
and at the final follow-up visit at 8 weeks.
Measurements
Baseline characteristics and measurement of predictor
variables
Data are collected at baseline for relevant participant
demographic and clinical characteristics. We use pro-
grammed portable monitors to obtain ambulatory
blood-pressure readings at 30-minute intervals through-
out the whole day, and every 60 minutes at night. We
define daytime as the interval from 10 AM to 8 PM, and
nighttime as the interval from midnight to 6 AM. These
fixed intervals eliminate the transition periods in the
morning and evening when blood pressure changes rap-
idly, resulting in daytime and night-time blood pressure
levels that are within 1 to 2 mm Hg of the awake and
asleep levels. Within individual subjects, we weigh the
means of the ambulatory blood pressure by the interval
between readings [28].
All vascular risk factors are measured in a standard-
ized fashion, consistent with methods used in INTER-
HEART and INTERSTROKE studies [29,30]. Laboratory
specimens are collected during baseline and at the 8-
week follow-up period. Frozen samples will be analyzed
at the GUH laboratory by using standardized storage,
handling, and analytic procedures at the end of the trial.Trained researchers administer the questionnaires
(SCI, ISI, PSQI, BDI, and BAI). The data are entered
into an electronic case-report form by a trained member
of the research team. The following data points are
collected:
1. Demographics: date of birth, age, sex, employment status
2. Co-morbidities: history of diabetes mellitus, atrial
fibrillation, dialysis, chronic renal disease, chronic
kidney disease, congestive heart failure, dyslipidemia,
nocturnal asthma attacks, peripheral vascular
disease, current smoker (or smoked within last
6 months), mean number of cigarettes smoked per
day, alcohol intake, caffeine intake, and level of
physical activity
3. Resting heart rate
4. Blood pressure (calibrated, identical machines are
used on all participants)
a. Office automated SBP (mm Hg)
b. Office automated DBP (mm Hg)
c. Mean 24-hour ambulatory SBP (mm Hg)
d. Mean 24-hour ambulatory DBP (mm Hg)
e. Daytime peak SBP (mm Hg)
f. Daytime peak DBP (mm Hg)
g. Nighttime peak SBP (mm Hg)
h. Nighttime peak DBP (mm Hg)
i. Mean daytime SBP (mm Hg)
j. Mean daytime DBP (mm Hg)
k. Mean nighttime SBP (mm Hg)
l. Mean nighttime DBP (mm Hg)
5. Current medications: – antihypertensives, statins,
other lipid-lowering agents, antithrombotic therapy,
oral hypoglycemic agents, insulin, sedatives/hypnotics,
and analgesics
6. Sleep questionnaires (PSQI, SCI, ISI)
a. PSQI score
b. PSQI >5
c. Time in bed
d. SOL
e. WASO
f. Total sleeping time (TST)
g. Sleep efficiency
h. SCI score
i. SCI score ≤5.9
j. ISI score
k. ISI score ≥15
7. BAI score
8. BDI score
9. Height, weight, BMI (calculated by using a standard
automated weighing scale and a Leicester height
measure)
10.Laboratory measurements (nonfasting samples)
a. Plasma lipoproteins: total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C),
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triglycerides (TGs), apolipoprotein B (ApoB),




Change in mean 24-hour ambulatory SBP between base-
line and 8 weeks of follow-up. Hypertension has been
selected as the primary outcome measure because of its
robust association with inadequate sleep and its well-
documented association with CVD.
Secondary outcomes
1. Change in mean 24-hour DBP between baseline and
8 weeks of follow-up.
2. Change in
a) Daytime peak SBP
b) Daytime peak DBP
c) Nighttime peak SBP
d) Nighttime peak DBP
e) Mean daytime SBP
f) Mean daytime DBP
g) Mean nighttime SBP
h) Mean nighttime DBP
3. Change in BMI
4. Change in plasma lipoproteins (TC, LDL-C, HDL-C,
TG, ApoB, ApoA1)
5. Change in HbA1c
6. Change in eGFR
7. Change in smoking status
8. Change in mean number of cigarettes smoked per
day
9. Change in SCI score
10.Change in ISI score
11.Change in PSQI score
12.Change in SOL
13.Change in WASO
14.Change in total sleep time
15.Change in sleep efficiency
16.Change in proportion of participants with SE ≥85%
at 8 weeks
17.Change in proportion of participants with SOL
≤30 minutes at 8 weeks
18.Change in proportion of participants with PSQI <5
at 8 weeks
19.Change in proportion of participants with SCI
score ≤5.9 at 8 weeks
20.Change in proportion of participants with ISI
score ≥15 at 8 weeks
21.Change in BDI score
22.Change in BAI scoreCointerventions
Participants in this trial will ideally not receive any anti-
hypertensive medications throughout the 8-week period.
However, participants receiving up to two antihyperten-
sive agents at the time of entry into the trial are eligible
for inclusion, provided that no recent (within the previ-
ous 8 weeks) changes occurred in type or dose of antihy-
pertensive medications and there are no planned change
to antihypertensive medication over the next 8 weeks
(during the trial). Note: in patients with mild hyperten-
sion and no history of CVD, current guidelines recom-
mend an initial period of lifestyle intervention, consistent
with our approach. Treating clinicians will be permitted
to use clinical judgment in initiating and dose-adjusting
antihypertensive therapies for both study groups during
the 8-week trial, where appropriate. Participants who are
stable on cardiovascular preventive therapies (no change
in previous 3 months), such as lipid-lowering agents, an-
tithrombotic therapies, oral hypoglycemic agents, and
insulin will continue their usual treatment. Participants
not taking these agents will be encouraged to avoid initi-
ation of treatment with these agents, until the 8-week
trial period has been completed. However, treating clini-
cians will be permitted to use usual clinical judgment in
initiating and dose-adjusting such medications, where
appropriate. Initiation and/or dose adjusting of cointer-
ventions will be recorded and measured and accounted
for using sensitivity analysis. Participant adherence to
the intervention will also be measured, and adjusted for
using sensitivity analysis. For example, we will analyze
the data for evidence of a dose/response relation be-
tween degree of reduction in SBP and number of online
sleep sessions completed.Sample-size calculation
The primary outcome is the mean difference in SBP re-
duction over the 8-week period between the two study
groups. Our estimated minimum clinically meaningful
effect size is 5 mm Hg, with an estimated standard devi-
ation (SD) for SBP reduction of 8.3 mm Hg in the inter-
vention group and 7.7 mm Hg in the control group,
based on previous research [31]. The minimum effect
size is based on previous randomized controlled trials
reporting a reduction in CVD with reductions in SBP of
5 mm Hg or greater, and the reduction in blood pressure
with lifestyle interventions observed in previous trials
[31-33]. A 5.6-mm Hg reduction in blood pressure in
the ADVANCE trial resulted in relative-risk reductions
of 9% for major vascular events, and 18% for cardiovas-
cular death [34]. Based on a two-sample comparison of
means at a significance level of α = 0.05 and power of
80% to detect a difference of 4 mm Hg (power of 90% to
detect a difference of 5 mm Hg) between treatment
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group sample size of 67 participants will be required.
Statistical analysis plan
Descriptive statistics and baseline characteristics
Descriptive statistics will be used to describe the baseline
characteristics of the study sample, the flow of trial par-
ticipants, and the level of missing data for both predictor
and outcome variables. All losses to follow-up and drop-
outs will be counted, and where possible, reasons docu-
mented. Categoric variables will be described by using
frequencies and percentages. Histograms and boxplots
will be used to evaluate the distribution of continuous
variables and to identify any outliers or potential errors
in the data, with follow-up verification if necessary from
the case-report forms. For continuous variables, the
mean and standard deviation will be used to describe
the typical value and spread in the sample. For continu-
ous variables that are not normally distributed, the me-
dian and interquartile range will be used to describe the
typical value and spread in the sample. All tests of sig-
nificance will be two-sided and conducted at an α = 0.05
for level of statistical significance.
Statistical analysis
The primary analysis will use the on-treatment dataset for
all outcomes. On-treatment is defined as those participants
who completed at least one session of the online sleep
intervention. A secondary analysis will use the intention-
to-treat dataset, and a third, per-protocol analysis, will also
be carried out for all outcomes, with postrandomization
exclusions due to ineligibility, noncompliance, loss to fol-
low–up, or missing data.
A linear mixed model will be used to compare changes
in mean 24-hour ambulatory SBP (and other secondary
outcomes) from baseline to 8 weeks after randomization.
We will adjust for covariates associated with the inter-
vention and the outcome as appropriate (for example,
age, baseline SBP, baseline DBP, baseline SCI score). The
selection of explanatory variables for inclusion in the
final model will be based on clinical plausibility and vari-
able selection routines, the LASSO, and regression trees.
It will be assumed that missing data are missing at ran-
dom and therefore accounted for in the mixed model.
The validity of this assumption will be investigated by
looking at the missing data patterns and by modeling
the probability of missing data based on the explanatory
variables available. The sensitivity of the missing value-
generating mechanism to the choice of variables for in-
clusion and the final conclusions will be assessed by
using multiple imputations via chained equations and
predictive mean matching. Model checking will be per-
formed by using suitable model diagnostics and residual
plots. All statistical analyses will be performed by usingthe software packages SPSS version 21.0, R version
2.15.3 and Minitab version 16.2.
Subgroup and sensitivity analyses
The primary outcome will be analyzed by subgroups
based on
a) Age (≥65 years versus <65 years)
b) Sex
c) Severity of hypertension at baseline (SBP 130 to 150
versus 151 to 160)
d) Use of antihypertensive medication at time of entry
into the trial
e) Introduction of antihypertensive medication during
the trial
f ) Sleep condition indicator score ≤5.9 versus >6.0
g) Body mass index (BMI ≤25 versus >25)
h) Employment status
i) Concomitant use of hypnotics
j) Depression, score ≥17 versus <17 on BDI
k) Anxiety, score ≥22 versus <22 on BAI
l) Adherence to the intervention
Statistical tests of interaction will be performed for all
subgroup analyses. A sensitivity analysis will be performed
to assess the influence of adherence to the intervention,
on the estimated treatment effect. These analyses will use
the on-treatment dataset.
Ethical approval
This study has received ethical approval from the re-
search ethics committee at GUH (ref CA 864).
Trial management and quality control
Clinical site
This single-center study will be conducted at Croí
House, and the coordinating center will be located at the
HRB-CRFG, National University of Ireland, Galway.
Steering committee and local operations committee
The steering committee will consist of Prof. Martin
O’Donnell (Principal investigator), Dr. Emer McGrath
(Principal investigator), Mr. Neil Johnson (Croí House),
Prof. Andrew Murphy (co-investigator), Dr. John Newell
(statistician) and Prof. Colin Espie (University of Glasgow,
co-investigator).
Data collection and quality control
All data collection and all study-outcome measure-
ments are conducted locally. Data are entered into an
electronic case-report form by the attending researcher.
Data entered include participant identification numbers,
verification of eligibility criteria, verification of written
informed consent, relevant participant demographic
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parameters such as blood pressure and BMI, adherence to
follow-up, adherence to the intervention, and question-
naire scores. All questionnaire scores are recalculated to
ensure validity. Laboratory results for HbA1c, lipoproteins,
and eGFR will be automatically entered into the GUH
database and will be manually entered into the electronic
case-report forms and trial database.
All study personnel are blinded to study-group assign-
ment and will remain blinded until all data have been
collated, entered into the database, the full dataset has
been blindly reviewed for errors, and statistical analyses
have been completed. Blinding will thus help to avoid
differential measurement bias or biased data entry.
To ensure that high-quality data are collected, staff
receive training on completing case-report forms. In
addition, central statistical monitoring of the data by
using data-entry edit checks is used, to improve the val-
idity of the data-entry process.
Discussion
Methods of minimizing bias
One potential limitation of this study is the risk of con-
tamination, if participants or clinicians become aware of
individual treatment-group assignments. This could re-
sult in the differential use of co-interventions between
the two study groups, or use of a sleep intervention in
the control group, resulting in bias toward the null. The
screening questionnaire for sleep quality is another po-
tential source of unblinding. To minimize the risk of
unblinding, it is being administered as a routine baseline
screen, along with questionnaires to measure depression,
anxiety, and cognitive function.
A second potential limitation is volunteer bias. Indi-
viduals who participate in studies are often more healthy
than those who refuse to provide consent. Thus, the ac-
tual sample of individuals included in the trial may not
be representative of the relevant population, limiting the
generalizability of the results. Furthermore, study volun-
teers are often well-motivated, highly adherent individ-
uals who are likely to benefit from such an intervention.
This would also affect the external validity of the results.
However, this is a proof-of-concept, phase II study, and
such a population will maximize the chances of detect-
ing the true treatment effect, before testing the effective-
ness of this intervention in a wider population.
A third potential limitation in this study is the primary
outcome measure of reduction in mean 24-hour systolic
blood pressure, which is a surrogate outcome measure.
As this is a pilot study, a clinical outcome would not be
feasible, as a relatively long follow-up period would be
required to demonstrate a treatment effect. Reduction in
blood pressure has been shown to be predictive of sig-
nificant reductions in major vascular events. Thus, webelieve that reduction of systolic blood pressure is an ap-
propriate outcome measure for this study.
A fourth potential limitation of this study is the risk of
nonadherence to the intervention, which is a particular
challenge in trials evaluating behavioral interventions.
However, a number of measures are being implemented
to maximize adherence (see earlier). To determine the
influence of adherence on the estimated treatment ef-
fect, a sensitivity analysis will be performed.
A fifth potential limitation is that patients with undiag-
nosed OSA may be included in this study, which could
undermine our ability to detect a true treatment effect,
given that such patients may not be expected to improve
with the intervention. Thus, we have excluded patients
with a known diagnosis of treated OSA, to minimize this
potential limitation. Finally, our results could be subject
to attention bias, due to differences in the level of atten-
tion provided to the two treatment groups. However,
given that this is a phase II, proof-of-concept study, with
the aim of maximizing the chances of detecting a true
treatment effect, we elected not to use an attention pla-
cebo in the control arm. If a significant treatment effect
is observed in this pilot study, a larger-scale phase III
trial will be performed, with the inclusion of an attention
placebo in the control arm, to demonstrate the effective-
ness of this intervention in a broader population of pa-
tients for primary and secondary prevention of CVD.
Trial status
Ongoing, participant recruitment under way.
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